What MACI success rates actually look like

The numbers behind MACI — matrix-induced autologous chondrocyte implantation — are better documented than those for almost any other cartilage repair technique currently in routine use.

The strongest single piece of evidence is the SUMMIT Phase 3 randomised controlled trial (N=144, mean lesion size 4.8 cm²), which found MACI statistically significantly superior to microfracture across every KOOS domain at two years: pain and function (P=0.001), activities of daily living (P<0.001), quality of life (P=0.029), and symptoms (P<0.001). That superiority was maintained at five years — an unusual degree of trial-level durability for any cartilage procedure.

The ten-year picture comes from a prospective Australian registry reported by Ebert and colleagues in 2024 (204 patients enrolled; 168 reviewed clinically). Patient-reported outcomes improved substantially in the first two years, then held stable with no statistically significant change from year two through year ten. MRI MOCART scores followed the same pattern. At the decade mark, 92% of patients were satisfied with their pain relief, and 76% reported satisfaction with their ability to participate in sport.

A parallel systematic review of minimum ten-year outcomes (168 patients, 188 defects) recorded a 9.0% all-cause reoperation rate and 7.4% progression to total knee arthroplasty over ten to seventeen years. In a population selected for complex focal lesions — often where simpler options had already been considered or tried — these figures represent durable preservation of the native joint in the substantial majority of cases.

Why MACI is always a two-stage procedure

Understanding why MACI cannot be performed in a single operative episode matters before comparing it with alternatives.

The procedure depends on culturing the patient's own chondrocytes in a laboratory. During a first, brief arthroscopic procedure, a small cartilage sample (roughly 200–300 mg) is harvested from a low-load area of the knee. That tissue is then sent to a specialist laboratory, where the chondrocytes are isolated, multiplied, and seeded onto a Type I/III collagen membrane over a period of four to eight weeks. Only once that cell-seeded membrane is ready can the second, open implantation take place.

There is no shortcut to this biology. Cell expansion cannot be compressed into a single anaesthetic episode, which means no single-stage MACI variant exists — and the phrase 'single-stage versus two-stage MACI' describes something that is not clinically possible.

For patients, two-stage means two anaesthetic events and a four-to-eight-week gap between them before rehabilitation can properly begin — a meaningful practical consideration.

The meaningful comparison is therefore MACI (two-stage, cell-based) against procedures that are genuinely completable in one visit: AMIC, minced cartilage implantation, and BMAC-augmented scaffolds. That is the axis the rest of this article examines.

Single-stage alternatives: what the evidence shows so far

The short-term data for single-stage alternatives are encouraging — and the equivalence at two years is not marginal.

A 2025 matched-pair study (N=48; 16 patients per arm) compared MACI, AMIC, and minced cartilage implantation directly. All three procedures produced statistically significant improvements in VAS pain, KOOS-Pain, and KOOS-Symptoms from baseline, with no significant between-group differences at two years and low complication rates across every arm. A separate 2020 multicentre study of freshly isolated autologous chondrocytes implanted in a PolyActive scaffold (N=40) added structural support: every patient achieved at least 67% MRI fill at 24 months, and hyaline-like repair tissue was confirmed in 22 of 31 biopsied patients (71%).

For patients for whom the weeks-long cell-expansion wait and a second anaesthetic represent a meaningful obstacle, that two-year performance matters. Single-stage procedures involve one operative event, no laboratory phase, and substantially lower logistical complexity — advantages that are clinically significant for appropriate candidates, particularly where access to a two-visit pathway is limited.

Longer-term data do exist for some single-stage approaches: HA-BMAC registry data from one centre show 88% graft survival at ten years, broadly in range with MACI's published figures. The limitation is that this comes from a single centre and carries no RCT comparison against MACI or any other modality.

That is the current boundary of the evidence. No long-term randomised trial beyond five years has directly compared any single-stage repair to MACI. Two-year matched equivalence cannot confirm that repaired tissue holds under sustained high-impact loading over a decade. Single-stage procedures are appropriately described as offering equivalent short-term efficacy and lower procedural burden — but unproven long-term durability relative to MACI. The trials needed to resolve this question have yet to report.

When early results don't hold: the salvage context

One dataset in the MACI literature deserves closer attention precisely because it complicates an otherwise positive picture.

A small prospective New Zealand series followed 15 patients who underwent MACI after a prior failed microfracture procedure, with a mean defect size of 3.76 cm². At two years, MRI fill stood at 90% — in line with figures from primary repair cohorts. By ten years, that had fallen to 49%, biopsies showed fibrocartilage in 73% of cases rather than hyaline-like tissue, and outcome scores were declining.

The critical context is that all 15 patients were undergoing salvage repair. Microfracture disrupts the subchondral bone plate — the mineralised layer that underpins stable cartilage attachment — and that disruption appears to compromise the environment for any subsequent repair attempt, regardless of technique. These results most likely reflect the biological difficulty of the salvage setting rather than a signal about de-novo MACI performance in well-selected primary candidates.

The transferable lesson, however, applies across repair modalities: early MRI fill at 12 to 24 months is a useful indicator of initial graft incorporation, not a guarantee of sustained hyaline restoration at ten years. Patients and clinicians evaluating any cartilage repair procedure — single-stage or two-stage — should treat short-term imaging optimism with appropriate caution, and ask specifically whether outcome data come from primary or salvage cohorts.

Who is suitable and what moderates outcomes

Defect size is the most consistently cited clinical moderator. The SUMMIT trial's subgroup analysis found the strongest MACI advantage in patients with lesions of 3 cm² or larger — the threshold where marrow-stimulation techniques tend to underperform most noticeably. Both MACI and ACI are broadly indicated for focal defects in the 2–10 cm² range; single-stage alternatives such as AMIC and minced cartilage implantation may suit lesions toward the smaller end of that window, though the evidence for size-stratified head-to-head comparisons remains limited.

Age matters, though not as an absolute ceiling. Published series across all repair modalities consistently show stronger outcomes in patients under 40. A 45-year-old with a well-contained defect, no significant surrounding osteoarthritis, and intact joint mechanics may still be a reasonable candidate for either pathway — but age is a variable to weigh openly in consultation rather than set aside.

Both pathways share the same mechanical prerequisites and the same exclusions. Diffuse or bipolar osteoarthritis, uncorrected malalignment, and ligamentous instability all compromise the environment on which durable cartilage repair depends. Neither single-stage nor two-stage techniques are indicated where these problems remain unresolved.

Where malalignment coexists with a focally repairable lesion, a tibial or femoral osteotomy can convert an otherwise unsuitable joint into a viable repair environment by redistributing load across the compartment. This combination requires careful staging and confirmation that the lesion itself remains focal and repairable once alignment is corrected. MRI characterisation of defect depth, size, and surrounding bone quality — alongside a thorough mechanical assessment of alignment and stability — is what determines whether that combination, or indeed either repair pathway, is achievable. Symptom pattern alone cannot answer that question.

Getting a cartilage assessment in London

The evidence supports a clear decision framework: MACI's advantage is strongest for focal lesions of 3 cm² or larger in younger patients, where two operative episodes are an acceptable trade-off for a technique with 10-year outcome data. Single-stage alternatives — principally AMIC and minced cartilage implantation — offer equivalent short-term results with lower procedural burden, and suit cases where access, cost, or patient preference weigh against a two-stage pathway; their long-term durability relative to MACI remains unconfirmed by trials of equivalent length. Neither route is appropriate without first confirming that the joint's mechanical environment — alignment, stability, and defect containment — can support repair.

Translating that framework into an individual plan requires imaging review, mechanical assessment, and an honest discussion of what the patient is trying to preserve and over what timeframe. Professor Paul Y. F. Lee at the London Cartilage Clinic on Harley Street undertakes exactly this kind of specialist cartilage and joint-preservation assessment — to arrange one, visit londoncartilage.com.

1. [1] Comparison of Three Different Techniques — MACI Versus AMIC and Arthroscopic Minced Cartilage — 2-Year Follow-Up. (2025). https://doi.org/10.3390/jcm14072194 https://doi.org/10.3390/jcm14072194
2. [2] Matrix-Applied Characterized Autologous Cultured Chondrocytes Versus Microfracture: Five-Year Follow-up of a Prospective Randomized Trial. (2018). https://doi.org/10.1177/0363546518756976 https://doi.org/10.1177/0363546518756976
3. [3] SUMMIT Prospective, Randomized, Controlled Trial: Response Rates To MACI Versus Microfracture By Lesion Characteristics. (2013). https://doi.org/10.1177/2325967113S00029 https://doi.org/10.1177/2325967113S00029
4. [4] 10-Year Prospective Clinical and Radiological Evaluation After Matrix-Induced Autologous Chondrocyte Implantation and Comparison of Tibiofemoral and Patellofemoral Graft Outcomes. (2024). https://doi.org/10.1177/03635465241227969 https://doi.org/10.1177/03635465241227969
5. [5] A Prospective Outcome, MRI and Biopsy Study of MACI Cartilage Transplantation. (2017). https://doi.org/10.1177/2325967117S00186 https://doi.org/10.1177/2325967117S00186
6. [6] Minimum 10-Year Outcomes of Matrix-Induced Autologous Chondrocyte Implantation in the Knee. (2024). https://doi.org/10.1177/03635465231205309 https://doi.org/10.1177/03635465231205309
7. [7] Single-Stage Autologous Chondrocyte-Based Treatment for Knee Cartilage Lesions: Two-Year Follow-up of a Prospective Multicenter Study. (2020). https://doi.org/10.1177/0363546520912444 https://doi.org/10.1177/0363546520912444